January 04, 2019
Rose
In the first major pharmaceutical deal of 2019, Bristol-Myers Squibb says it will buy Celgene, a maker of cancer-fighting drugs, in a merger valued at $74 billion. According to Stat, Bristol-Myers has been under pressure to set a new course since August 2016, when a big study of its cancer immunotherapy, Opdivo, failed to show a benefit in previously untreated patients with non-small cell lung cancer. Analysts look at what the deal means to the industry at large.
from Kaiser Health News http://bit.ly/2s8WUhw
January 04, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
A Look Inside Army’s Efforts To Create Coronavirus Strains To Support Vaccine Research- Planning Underway To Help U.S. Physicians Make Tough Ethical Decisions On Who To Treat Amid Equipment Shortages
- Unsubcribing Times: All Those ‘Reassuring’ Emails From Companies Can Just Pile On More Anxiety
- Some Prisoners Released Early As Crowded Jails Fear Prospect Of Widespread Outbreaks
- Some Local Governments Try To Address Raising Economic Concern By Halting Evictions
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment